Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Claritin, Alavert, Advil Allergy Sinus Head Major OTC Approvals In 2002

This article was originally published in The Tan Sheet

Executive Summary

Antihistamines accounted for the most prominent OTC approvals in 2002, with Schering-Plough Healthcare Products' Claritin franchise and Wyeth Consumer Healthcare's Alavert and Advil Allergy Sinus all receiving the FDA go-ahead during the year

You may also be interested in...



OTC Labeling Adopted By FDA In Forced Switch Would Violate Regs Comments Say

FDA could not adopt a drug's approved OTC label from another country as acceptable U.S. OTC labeling without violating its own regulations, according to the American Association of Physicians & Surgeons and Competitive Enterprise Institute

OTC Labeling Adopted By FDA In Forced Switch Would Violate Regs Comments Say

FDA could not adopt a drug's approved OTC label from another country as acceptable U.S. OTC labeling without violating its own regulations, according to the American Association of Physicians & Surgeons and Competitive Enterprise Institute

OTC Labeling Adopted By FDA In Forced Switch Would Violate Regs Comments Say

FDA could not adopt a drug's approved OTC label from another country as acceptable U.S. OTC labeling without violating its own regulations, according to the American Association of Physicians & Surgeons and Competitive Enterprise Institute

Related Content

Topics

UsernamePublicRestriction

Register

OM013658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel